Skip to content
Lupus Association of NSW Inc.
Lupus Association of NSW Inc.
The Quest for a Cure
1800 802 088

Donate Now

  • Home
  • Understanding Lupus
    • What is Lupus?
    • Signs and Symptoms of Lupus
    • Diagnosing Lupus
    • FAQs about Lupus
  • Living with Lupus
    • Lupus and COVID-19
    • Coronavirus, stress and mental health
    • Looking after your well-being
    • Tips for Living with Lupus
    • Lupus and Diet
    • Medications
    • Managing Pain
    • Managing Fatigue
    • Infections
    • Photosensitivity
  • Sjogren’s Syndrome
    • What is Sjögren’s Syndrome?
    • Signs and Symptoms of Sjögren’s
    • Diagnosing Sjögren’s Syndrome
    • Treating Sjögren’s Syndrome
    • Tips for Living with Sjögren’s Syndrome
  • Resources
    • Support
    • Other Lupus Websites
    • Lupus Store
  • Research
    • Research and Reports
    • The Monash Lupus Clinic
    • The Alpha Project
    • The Alpha Project Phase 11
  • Get Involved
    • News and Events
    • Lupus Stories
    • Donate
  • About Us
    • Mission Statement
    • Our History
    • Contact
    • Privacy Policy
  • Home
  • Understanding Lupus
    • What is Lupus?
    • Signs and Symptoms of Lupus
    • Diagnosing Lupus
    • FAQs about Lupus
  • Living with Lupus
    • Lupus and COVID-19
    • Coronavirus, stress and mental health
    • Looking after your well-being
    • Tips for Living with Lupus
    • Lupus and Diet
    • Medications
    • Managing Pain
    • Managing Fatigue
    • Infections
    • Photosensitivity
  • Sjogren’s Syndrome
    • What is Sjögren’s Syndrome?
    • Signs and Symptoms of Sjögren’s
    • Diagnosing Sjögren’s Syndrome
    • Treating Sjögren’s Syndrome
    • Tips for Living with Sjögren’s Syndrome
  • Resources
    • Support
    • Other Lupus Websites
    • Lupus Store
  • Research
    • Research and Reports
    • The Monash Lupus Clinic
    • The Alpha Project
    • The Alpha Project Phase 11
  • Get Involved
    • News and Events
    • Lupus Stories
    • Donate
  • About Us
    • Mission Statement
    • Our History
    • Contact
    • Privacy Policy

Research Improving Clinical Trial Design

Researchers face multiple obstacles that can hinder their ability to show whether a potential lupus treatment works or may be better than a current treatment. Years of disappointing results in lupus drug development demonstrates that a different approach is needed.

In 2009, the Lupus Foundation of America established the LFA Collective Data Analysis Initiative (LFA CDAI), a first-in-lupus collaboration among multiple companies with a shared goal – to improve clinical trials so we can have an arsenal of treatments needed for people living with lupus.

Since its inception, LFA CDAI has published important findings on the impact of background medications taken by people with lupus during clinical trials. The latest LFA CDAI analysis builds upon this work.

In this study, researchers looked at the long-term effects of a potential treatment on health outcomes. The results showed that shorter Phase 2 clinical trials may not be effective at predicting outcomes in longer clinical trials.

Researchers also found that response rates to the standard of care treatment are affected by the severity of the disease and the aggressiveness of background immuno-suppressive treatments, which has implications for the selection of participants in future clinical trials.

The results from this study can be used by the lupus clinical trials community to improve the design of future studies and to accelerate the identification of effective new therapies that would ultimately benefit everyone who suffers from lupus.

In an earlier CDAI study, researchers found that the use of many different kinds of background medications in lupus trials results in high response rates among placebo groups. This makes it challenging to evaluate new treatments that might be safer or more effective.

The analysis includes some insights that can help people who design clinical trials come up with ways to improve study designs, in order to be able to see whether an investigational treatment has advantages over current options.

These studies will help the lupus research community conduct stronger clinical trials that produce more meaningful data, which will accelerate the development of new therapies.

Author: lupus

Post navigation

PreviousPrevious post:World Lupus Day 2017NextNext post:Exercising with Lupus

Related posts

WLF Global Survey of People Living with Lupus
05/05/2022
New cutaneous lupus erythematosus clinical trial in Victoria
13/09/2021
FDA Approves Saphnelo™ as New Treatment for Lupus
06/08/2021
Exercise Intervention
02/06/2021
US FDA approves Lupkynis (voclosporin)
16/02/2021
US FDA approve Benlysta
16/02/2021
Items in this Section
Stay in touch
Address: 55 Wicks Rd
North Ryde NSW 2113
 
Phone: (02) 9878 6055
Email: info@lupusaust.org.au
A.B.N: 25 876 911 996
Useful Links
  • Other Lupus Websites
Latest Tweets
World Lupus Day is Wednesday May 10. Let's work together to raise awareness and beat this monster!
Donations
  • How To Donate
  • Privacy Policy
Donate Now!
© Lupus Association of NSW Inc.

Webmaster - admin@lupusnsw.org.au